News
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress,…
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the…
Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition with a more chronic course and less variability of symptoms throughout the day. The study presented…
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium…
New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments have mainly targeted the mesolimbic dopamine pathway in the CNS and D2 receptors. However, the cited…
Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides…
Is the combination of tiotropium/olodaterol proven more effective in reducing the risk of clinically significant worsening of COPD compared to monotherapy?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), the use of a composite parameter that includes lung function, the occurrence of exacerbations, and quality of life offers a…
Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various aspects of patients' lives and the economic burden this long-term disease, without available causal…
Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.
Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors…
The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The…
Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019, international recommendations for the nutrition of individuals at risk of or already with pressure ulcers…
Classification and Management of Chronic Wounds
Chronic wounds are common comorbidities that increase the morbidity and mortality of patients. Common types of chronic wounds on the lower extremities include arterial, venous, and diabetic ulcers,…
Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been increasing in recent years. Currently, diabetics make up approximately 8−10% of the population. The…
Popular this week
- Reproductive postponement as a clinical problem: biological limits, reproductive difficulties and psychosexual impact on the couple
- Ambient artificial intelligence for clinical documentation: evidence, legislative framework and implementation in clinical practice
- Artificial intelligence in dentistry: from second reading of bite-wing radiographs to dental practice management
- Hemorrhagic shock and treatment of severe bleeding
- Vaccination of children against seasonal flu